Get the Stockscreener App
5.59
5.67%
0.30
After Hours:
5.59
Nevro Corp stock is traded at $5.59, with a volume of 696.92K.
It is up +5.67% in the last 24 hours and down -9.69% over the past month.
See More
Previous Close:
$5.29
Open:
$5.24
24h Volume:
696.92K
Relative Volume:
1.05
Market Cap:
$218.11M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
559.00
EPS:
0.01
Net Cash Flow:
$-67.42M
1W Performance:
-2.27%
1M Performance:
-9.69%
6M Performance:
-61.29%
1Y Performance:
-70.92%
1-Day Range:
$5.1501
$5.67
1-Week Range:
$5.00
$5.81
52-Week Range:
$4.382
$22.64
Nevro Corp Stock (NVRO) Company Profile
Name
Nevro Corp
Sector
Industry
Phone
650-251-0005
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-21-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| May-31-23 | Initiated | RBC Capital Mkts | Outperform |
| May-15-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Jan-17-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Downgrade | Piper Sandler | Neutral → Underweight |
| Dec-20-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Apr-13-22 | Resumed | Truist | Hold |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-09-21 | Downgrade | Truist | Buy → Hold |
| Aug-05-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-05-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-05-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-09-21 | Downgrade | Redburn | Buy → Neutral |
| Jul-06-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-02-21 | Initiated | Piper Sandler | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-08-20 | Upgrade | UBS | Sell → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Mar-20-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-20-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-28-18 | Initiated | UBS | Sell |
| Nov-07-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-06-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-06-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-19-18 | Downgrade | Goldman | Neutral → Sell |
| Jul-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-18 | Reiterated | Canaccord Genuity | Buy |
| May-08-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-08-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
View All
Nevro Corp Stock (NVRO) Latest News
Nevro Corp.'s SWOT analysis: stock faces headwinds amid SCS market challenges - Investing.com UK
Nevro obtains FDA approval for AI-based spinal cord stimulation system - MSN
Where are the Opportunities in (NVRO) - Stock Traders Daily
Here's Why you Should Retain Nevro Stock in Your Portfolio Now - Yahoo Finance
Nevro Corp. (NYSE:NVRO) Shares Sold by Fred Alger Management LLC - MarketBeat
NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform - Yahoo Finance
Nevro obtains FDA approval for AI-based spinal cord stimulation system - Medical Device Network
Nevro wins FDA nod for AI-driven spinal cord stimulation tech - Mass Device
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation - PR Newswire
Nevro announces new inducement grants - Medical Buyer
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - StockTitan
Global Electrotherapy System Research Report 2024: A $1.65 Billion Market by 2030 - GlobeNewswire Inc.
Nevro Corp. (NYSE:NVRO) Stake Raised by Acadian Asset Management LLC - MarketBeat
Vanguard Group Inc's Strategic Reduction in Nevro Corp Holdings - Yahoo Finance
Nevro Corp. (NYSE:NVRO) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Nevro (NYSE:NVRO) Share Price Passes Below 50-Day Moving Average of $7.62 - MarketBeat
Microelectronic Medical Implants Market Report 2024-2029, with Profiles of Leading Players, including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro - Yahoo Finance UK
(NVRO) Trading Report - Stock Traders Daily
SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 817 shares, decreasing direct ownership by 0.50% to 163,590 units (SEC Form 4) - Quantisnow
Nevro to Present at Wells Fargo 2024 Healthcare Conference - The Malaysian Reserve
Nevro to Present at Wells Fargo 2024 Healthcare Conference - MSN
Nevro to Present at Wells Fargo 2024 Healthcare Conference - PR Newswire
Here's Why You Should Retain Nevro (NVRO) Stock for Now - MSN
Nevro (NYSE:NVRO) Lowered to "Sell" at StockNews.com - MarketBeat
Here's Why You Should Retain Nevro (NVRO) Stock for Now - Zacks Investment Research
Here's Why You Should Retain Nevro (NVRO) Stock for Now - Yahoo Finance
Assenagon Asset Management S.A. Has $6.13 Million Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
Nathan B Pliam Net Worth (2024) - GuruFocus.com
Nevro Corp. (NYSE:NVRO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Nevro Corp. (NYSE:NVRO) Given Average Rating of “Reduce” by Brokerages - Defense World
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Marketscreener.com
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - PR Newswire
Microelectronic Medical Implants Market Report 2024-2029, - GlobeNewswire
Microelectronic Medical Implants Market Report 2024-2029, with Profiles of Leading Players, including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro - Yahoo Finance
Engaged Capital Calls Nevro Corp. (NVRO) to Focus on Improving Profitability and Stop Pursuing Acquisitions - Insider Monkey
Engaged Capital Calls Nevro Corp. (NVRO) to Focus on Improving Profitability and Stop Pursuing Acquisitions - Yahoo Finance
Nevro Corp. (NYSE:NVRO) Shares Acquired by Price T Rowe Associates Inc. MD - Defense World
Head-To-Head Review: TriSalus Life Sciences (NASDAQ:TLSI) & Nevro (NYSE:NVRO) - Defense World
Truist Financial Lowers Nevro (NYSE:NVRO) Price Target to $5.50 - Defense World
Nevro (NYSE:NVRO) Price Target Cut to $8.00 by Analysts at Robert W. Baird - Defense World
Little Excitement Around Nevro Corp.'s (NYSE:NVRO) Revenues As Shares Take 34% Pounding - Simply Wall St
StockNews.com Downgrades Nevro (NYSE:NVRO) to Sell - Defense World
Nevro plunges as revised guidance draws downgrades - MSN
Nevro's (NVRO) Q2 Earnings Beat Estimates, Revenues Down Y/Y - MSN
Citi upgrades Nevro to neutral following sell-off - MSN
Citi upgrades Nevro to neutral following sell-off (NYSE:NVRO) - Seeking Alpha
Nevro seeks new path forward - BioWorld Online
Nevro: Not Having My Back (NYSE:NVRO) - Seeking Alpha
Q3 2024 EPS Estimates for Nevro Corp. (NYSE:NVRO) Cut by Analyst - MarketBeat
Nevro (NYSE:NVRO) Raised to "Neutral" at Citigroup - MarketBeat
Nevro (NYSE:NVRO) Upgraded to Neutral by Citigroup - Defense World
Nevro Corp Stock (NVRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):